Connect with us

Technology

OmniScience’s clinical trial genAI-powered control tower, Vivo, wins 1st place in the CNS Summit 2024 Innovation Showcase

Published

on

OmniScience was awarded top honors at the 2024 Innovation Showcase for its groundbreaking solution, Vivo – a market-first solution poised to transform clinical trial operation teams’ day-to-day workflow and ability to optimize trial insights with genAI

HOUSTON, Nov. 26, 2024 /PRNewswire-PRWeb/ — The CNS Summit (Collaborating for Novel Solutions) was founded in 2010 by life sciences leaders devoted to discovering better, more efficient ways to advance the life sciences industry through innovation, collaboration, and technology.

Patients are waiting: The CNS Summit brings together life sciences leaders who aren’t afraid to challenge the status quo when it comes to the development of new treatments for patients

At the November 2024 CNS Summit in Boston, OmniScience was awarded top honors at the Innovation Showcase for its groundbreaking solution, Vivo – a market-first solution poised to transform clinical trial operation teams’ day-to-day workflow and ability to optimize trial insights with genAI.

CNS Summit Chairman and Chief Curator, Dr. Amir Kalali, stated, “At CNS Summit, we are proud to support leading startups. The CNS Summit Innovation Showcase is a competitive process with independent judging that showcases the top new startups in the life science ecosystem.”

“This award is a testament to the transformative impact of Vivo and the dedication of our team at OmniScience,” said Angela Holmes, CEO of OmniScience. “Winning the Innovation Showcase validates our vision of unifying clinical trial data to empower teams with real-time insights that drive faster, smarter decisions. We are honored to be recognized by our peers and remain committed to advancing clinical development for better patient outcomes in neurology and psychiatry and beyond.”

The CNS Summit Innovation Showcase is a stage for forward-thinking companies to share solutions that address pressing challenges in clinical development. This year’s submissions underwent a rigorous peer-review process, with Vivo being selected as one of the top four finalists based on its innovation, novelty, and potential impact on clinical research. Judges of the summit ultimately awarded Vivo the top position, recognizing its ability to streamline data accessibility and support actionable insights that reduce clinical trial timelines and increase probability of success. Notable organizations in attendance at the 2024 Summit included AbbVie, AstraZeneca, Bayer, Bristol Myers Squibb, GSK, Johnson & Johnson, Novo Nordisk, Pfizer, Roche, and Takeda.

Driving Efficiency in Complex Trials and Addressing the Challenges of Siloed Data in Clinical Trials:

“Clinical trial complexity is skyrocketing, especially in CNS trials, where we’re dealing with diverse data types from labs, sensors, digital biomarkers, and imaging,” said Michael Bell, PhD, VP of Product at OmniScience, who led the showcase presentation. “Vivo changes the game for biopharma teams, enabling them to access on-demand insights, detect data discrepancies, forecast enrollment timelines, and monitor site, safety, and clinical metrics—all in one unified portal. Our team at OmniScience has drawn on years of experience in clinical data science to bring Vivo to life, and this win reinforces our commitment to accelerating therapeutic development.”

Vivo was developed to address the significant hurdles clinical operations teams face in managing siloed data, which impede timely, informed decision-making. During his presentation, Dr. Bell demonstrated how Vivo’s genAI capabilities allow teams to ask complex questions—such as identifying operational and safety risks and monitoring data quality and completeness—and receive instant, plain-language answers. Vivo’s AI-driven approach enables the delivery of proactive notifications, helping teams make informed adjustments throughout their trials.

Designed with explainability and interpretability at its core, Vivo ensures that every generated insight is supported by clear, traceable rationale grounded in data and clinical context. Its advanced cognitive architecture combines ontological knowledge of trial protocols with domain-specific clinical expertise, enabling qualitative and quantitative reasoning at scale.

“We are proud to be recognized by our peers for Vivo’s potential to transform how biopharma approaches clinical trial data,” Bell shared. “OmniScience has built a product that empowers study teams and their CROs with the oversight and insights they need to get critical treatments to patients faster.”

About the CNS Summit Innovation Showcase:

The CNS Summit Innovation Showcase is an annual opportunity for emerging companies to spotlight their innovative solutions in clinical research. This event brings together technology companies and industry leaders, creating a collaborative environment where groundbreaking ideas meet strategic partners. Through peer review, attendee voting, and independent judging, the showcase rewards innovation that has the potential to accelerate the development of life-changing therapies.

About OmniScience:

OmniScience is a trusted partner to leading life science organizations advancing clinical R&D missions through unparalleled expertise in clinical data science. Our expert team has served biopharma as a data science CRO, developing AI/ML solutions to translate complex clinical trial data into insights.

We believe in a future where all clinical trial data can be unified and translated into knowledge in real time. That’s why we created Vivo – your new favorite clinical development colleague.

Improve monitoring and oversight. Make better decisions with higher quality data. Reduce cost. Shorten timelines. If you would like to discuss how we can support your clinical trials, reach us at hello@omniscience.bio or on LinkedIn.

Media Contact
Carla Holloway, OmniScience, 1 3023790441, carla.holloway@omniscience.bio, omniscience.bio

View original content to download multimedia:https://www.prweb.com/releases/omnisciences-clinical-trial-genai-powered-control-tower-vivo-wins-1st-place-in-the-cns-summit-2024-innovation-showcase-302316131.html

SOURCE OmniScience

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Workday Names Rob Enslin President, Chief Commercial Officer

Published

on

By

Longtime SAP Veteran, Former UiPath CEO and Google Cloud President to Lead Workday’s Global Commercial Strategy for the Company’s Next Phase of Growth

PLEASANTON, Calif., Nov. 26, 2024 /PRNewswire/ — Workday, Inc. (NASDAQ: WDAY), a leading provider of solutions to help organizations manage their people and money, today announced the appointment of Rob Enslin to the newly created role of president, chief commercial officer (CCO). Enslin will be responsible for driving Workday’s revenue growth and leading the company’s global sales, partnership and customer experience efforts. 

Enslin brings more than 30 years of experience in the technology industry, most recently serving as CEO of UiPath where he led the company to non-GAAP profitability, advanced the company’s AI strategy, and drove expansion into new markets. Before joining UiPath, Enslin was president of cloud sales at Google Cloud, where he scaled the company’s sales operations and drove significant revenue growth. Enslin’s extensive career also includes 27 years at SAP, culminating in his role as president of the Cloud Business Group and executive board member. In addition to deep enterprise expertise, Enslin brings a strong global perspective, having held roles in South Africa, USA, Germany, and Japan throughout his career.

“Rob is a world-class leader with a track record of building high performing go-to-market teams, a deep understanding of industry and partner ecosystems, and unique global experience, making him the ideal leader to help guide Workday’s next phase of growth,” said Carl Eschenbach, CEO, Workday. “We’re confident that his vision and commitment to providing exceptional customer experiences will unlock even greater potential for Workday and businesses around the world.”

“Joining Workday at this pivotal moment is incredibly exciting,” said Enslin. “Workday’s unparalleled dataset, combined with its commitment to innovation, positions the company to become the definitive AI leader in the ERP market. I’m thrilled to be part of this transformation and shape the future of work.”

Enslin’s appointment will be effective as of December 2, 2024.

About Workday

Workday is a leading enterprise platform that helps organizations manage their most important assets – their people and money. The Workday platform is built with AI at the core to help customers elevate people, supercharge work, and move their business forever forward. Workday is used by more than 10,500 organizations around the world and across industries – from medium-sized businesses to more than 60% of the Fortune 500. For more information about Workday, visit workday.com.

© 2024 Workday, Inc. All rights reserved. Workday and the Workday logo are registered trademarks of Workday, Inc. All other brand and product names are trademarks or registered trademarks of their respective holders.

Forward-Looking Statements
This press release contains forward-looking statements including, among other things, statements regarding Workday’s leadership, growth, transformation, and potential. These forward-looking statements are based only on currently available information and our current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties, assumptions, and changes in circumstances that are difficult to predict and many of which are outside of our control. If the risks materialize, assumptions prove incorrect, or we experience unexpected changes in circumstances, actual results could differ materially from the results implied by these forward-looking statements, and therefore you should not rely on any forward-looking statements. Risks include, but are not limited to, risks described in our filings with the Securities and Exchange Commission (“SEC”), including our most recent report on Form 10-Q or Form 10-K and other reports that we have filed and will file with the SEC from time to time, which could cause actual results to vary from expectations. Workday assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this release, except as required by law.

Any unreleased services, features, or functions referenced in this document, our website, or other press releases or public statements that are not currently available are subject to change at Workday’s discretion and may not be delivered as planned or at all. Customers who purchase Workday services should make their purchase decisions based upon services, features, and functions that are currently available.

View original content to download multimedia:https://www.prnewswire.com/news-releases/workday-names-rob-enslin-president-chief-commercial-officer-302316896.html

SOURCE Workday Inc.

Continue Reading

Technology

Autodesk appoints Janesh Moorjani as chief financial officer

Published

on

By

SAN FRANCISCO, Nov. 26, 2024 /PRNewswire/ — Autodesk, Inc. (NASDAQ: ADSK) today announced the appointment of Janesh Moorjani as the company’s chief financial officer, effective December 16, 2024. Moorjani brings over 20 years of experience in the technology industry, with deep expertise in driving growth and efficiency at scale. Most recently, Moorjani served as CFO and COO of Elastic NV (NYSE: ESTC), the Search AI Company.

Reporting to chief executive officer Andrew Anagnost, Moorjani will lead and oversee Autodesk’s global finance organization. Moorjani will succeed interim chief financial officer Elizabeth “Betsy” Rafael, who will serve as an advisor to the company through the end of fiscal 2025 and will continue to serve on Autodesk’s Board of Directors, resuming her status as an independent director following the transition period and end of her employment by the company.

“We are excited to welcome such a high-caliber and seasoned CFO in Janesh,” said Andrew Anagnost, president and CEO of Autodesk. “His deep finance and software experience will be instrumental in supporting Autodesk’s continued momentum with sustained growth and enhanced profitability. I look forward to partnering with Janesh to drive Autodesk’s successful path forward and continue creating additional value for our stockholders. I also thank Betsy for stepping into the interim CFO role at an important time for Autodesk, and for her continued contributions both through the transition and as a qualified and experienced board member moving forward.”

Moorjani brings strong experience leading dynamic public software companies. He recently was CFO of Elastic since 2017 and assumed the additional responsibilities of COO in 2022. Prior to Elastic, he served in executive and leadership roles at Infoblox, VMware, Cisco, PTC, and Goldman Sachs. He currently serves on the Board of Directors of Cohesity, a leading AI-powered data security and data management company.

“I am thrilled to join Autodesk and work with Andrew, the company’s strong management team and the Board to capitalize on the compelling growth opportunities we have ahead,” said Moorjani. “Autodesk has established a clear leadership position as a technology innovator by providing differentiated and connected solutions that allow customers across industries to design and make anything. I look forward to working with the team to build on Autodesk’s strong financial foundation to drive continued growth, profitability and free cash flow to ultimately deliver sustainable stockholder value.”

ABOUT AUTODESK

The world’s designers, engineers, builders, and creators trust Autodesk to help them design and make anything. From the buildings we live and work in, to the cars we drive and the bridges we drive over. From the products we use and rely on, to the movies and games that inspire us. Autodesk’s Design and Make Platform unlocks the power of data to accelerate insights and automate processes, empowering our customers with the technology to create the world around us and deliver better outcomes for their business and the planet. For more information, visit autodesk.com or follow @autodesk. #MakeAnything

Autodesk is a registered trademark of Autodesk, Inc., and/or its subsidiaries and/or affiliates in the USA and/or other countries. All other brand names, product names or trademarks belong to their respective holders. Autodesk reserves the right to alter product and services offerings, and specifications and pricing at any time without notice, and is not responsible for typographical or graphical errors that may appear in this document.

SAFE HARBOR STATEMENT

This press release contains forward-looking statements that involve risks and uncertainties, including quotations from management, statements regarding our strategies, performance, results, growth, profitability and free cash flow, and all statements that are not historical facts. There are a significant number of factors that could cause actual results to differ materially from statements made in this press release, including: our strategy to develop and introduce new products and services and to move to platforms and capabilities, exposing us to risks such as limited customer acceptance (both new and existing customers), costs related to product defects, and large expenditures; global economic and political conditions, including changes in monetary and fiscal policy, foreign exchange headwinds, recessionary fears, supply chain disruptions, resulting inflationary pressures and hiring conditions; geopolitical tension and armed conflicts, and extreme weather events; costs and challenges associated with strategic acquisitions and investments; our ability to successfully implement and expand our transaction model; dependency on international revenue and operations, exposing us to significant international regulatory, economic, intellectual property, collections, currency exchange rate, taxation, political, and other risks, including risks related to the war against Ukraine launched by Russia and our exit from Russia and the current conflict between Israel and Hamas; inability to predict subscription renewal rates and their impact on our future revenue and operating results; existing and increased competition and rapidly evolving technological changes; fluctuation of our financial results, key metrics and other operating metrics; our transition from up front to annual billings for multi-year contracts; deriving a substantial portion of our net revenue from a small number of solutions, including our AutoCAD-based software products and collections; any failure to successfully execute and manage initiatives to realign or introduce new business and sales initiatives, including our new transaction model for Flex; net revenue, billings, earnings, cash flow, or new or existing subscriptions shortfalls; social and ethical issues relating to the use of artificial intelligence in our offerings; our ability to maintain security levels and service performance meeting the expectations of our customers, and the resources and costs required to avoid unanticipated downtime and prevent, detect and remediate performance degradation and security breaches; security incidents or other incidents compromising the integrity of our or our customers’ offerings, services, data, or intellectual property; reliance on third parties to provide us with a number of operational and technical services as well as software; our highly complex software, which may contain undetected errors, defects, or vulnerabilities; increasing regulatory focus on privacy issues and expanding laws; governmental export and import controls that could impair our ability to compete in international markets or subject us to liability if we violate the controls; protection of our intellectual property rights and intellectual property infringement claims from others; the government procurement process; fluctuations in currency exchange rates; our debt service obligations; and our investment portfolio consisting of a variety of investment vehicles that are subject to interest rate trends, market volatility, and other economic factors.

Further information on potential factors that could affect the financial results of Autodesk are included in Autodesk’s Form 10-K and subsequent Forms 10-Q, which are on file with the U.S. Securities and Exchange Commission. Autodesk disclaims any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/autodesk-appoints-janesh-moorjani-as-chief-financial-officer-302316577.html

SOURCE Autodesk, Inc.

Continue Reading

Technology

Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules

Published

on

By

MADISON, Wis., Nov. 26, 2024 /PRNewswire/ — Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Mike Murphy, the company’s new Vice President, Corporate Controller. As a material inducement to Mr. Murphy joining the company, and in accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee approved granting Mr. Murphy an award of 150,000 restricted stock units covering shares of the company’s common stock effective as of November 29, 2024 (collectively, the “Inducement Awards”). The Inducement Awards were made outside of the company’s current equity plan, but are subject to terms and conditions generally consistent with those in the company’s 2016 Equity Incentive Plan.

Twenty-five percent of the restricted stock units subject to the restricted stock unit award will vest on each yearly anniversary of October 31, 2024, subject to Mr. Murphy’s continued service through each applicable vesting date.

About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.

Media Contact
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-incorporated-reports-inducement-award-under-nasdaq-listing-rules-302316426.html

SOURCE Accuray Incorporated

Continue Reading

Trending